

# SCORE Search Results Details for Application 10558155 and Search Result 20081114\_104733\_us-10-558-155a-11.rng.

<a href="#">Score Home</a>	<a href="#">Retrieve Application</a>	<a href="#">SCORE System</a>	<a href="#">SCORE</a>	<a href="#">Comments /</a>
<a href="#">Page</a>	<a href="#">List</a>	<a href="#">Overview</a>	<a href="#">FAQ</a>	<a href="#">Suggestions</a>

This page gives you Search Results detail for the Application 10558155 and Search Result 20081114\_104733\_us-10-558-155a-11.rng.

[Go Back to previous page](#)

GenCore version 6.3  
Copyright (c) 1993 - 2008 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 14, 2008, 10:48:03 ; Search time 16 Seconds  
(without alignments)  
208777.913 Million cell updates/sec

Title: US-10-558-155A-11  
Perfect score: 236  
Sequence: 1 agcggcacacacuagguaca.....ggucucucugcagaucagu 236

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 11806651 seqs, 7113014948 residues

Total number of hits satisfying chosen parameters: 23613302

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N\_Geneseq\_200808:\*  
1: geneseqn1980s:\*  
2: geneseqn1990s:\*  
3: geneseqn2000:\*  
4: geneseqn2001a:\*  
5: geneseqn2001b:\*  
6: geneseqn2002a:\*  
7: geneseqn2002b:\*  
8: geneseqn2003a:\*  
9: geneseqn2003b:\*  
10: geneseqn2003c:\*  
11: geneseqn2003d:\*  
12: geneseqn2004a:\*  
13: geneseqn2004b:\*  
14: geneseqn2004c:\*  
15: geneseqn2004d:\*

16: geneseqn2004e:\*  
 17: geneseqn2004f:\*  
 18: geneseqn2005a:\*  
 19: geneseqn2005b:\*  
 20: geneseqn2005c:\*  
 21: geneseqn2006a:\*  
 22: geneseqn2006b:\*  
 23: geneseqn2006c:\*  
 24: geneseqn2006d:\*  
 25: geneseqn2007a:\*  
 26: geneseqn2007b:\*  
 27: geneseqn2007c:\*  
 28: geneseqn2007d:\*  
 29: geneseqn2008:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	236	100.0	236	18	ADV04745	Adv04745 Synthetic
2	236	100.0	239	18	AEC08836	Aec08836 HCV 3' UT
3	236	100.0	378	13	ADS34674	Ads34674 Hepatitis
4	236	100.0	7994	18	ADV04742	Adv04742 Replicon
5	236	100.0	8024	18	ADV04741	Adv04741 Replicon
6	236	100.0	8024	18	ADV04735	Adv04735 Replicon
7	236	100.0	8024	19	AED43513	Aed43513 Hepatitis
8	236	100.0	8024	21	AEL39639	Ael39639 HCV repli
9	236	100.0	9618	25	AER48939	Aer48939 Hepatitis
10	236	100.0	9666	21	AEK39271	Aek39271 Hepatitis
11	236	100.0	9666	21	AEK39272	Aek39272 Hepatitis
12	236	100.0	9666	21	AEK39273	Aek39273 Hepatitis
13	236	100.0	9666	25	AFR08182	Afr08182 Infectiou
14	236	100.0	9666	25	AFR08183	Afr08183 Infectiou
15	236	100.0	9666	25	AFR08184	Afr08184 Infectiou
16	236	100.0	9667	21	AEK39270	Aek39270 Hepatitis
17	236	100.0	9678	6	ABK88904	Abk88904 Human HCV
18	236	100.0	9678	18	ADV04737	Adv04737 Hepatitis
19	236	100.0	9678	25	AFR08179	Afr08179 Infectiou
20	236	100.0	9678	25	AFR08181	Afr08181 Infectiou
21	236	100.0	9678	25	AFR00383	Afr00383 Recombina
22	236	100.0	9707	18	AEC08840	Aec08840 Mutant re
23	236	100.0	9707	18	AEC08837	Aec08837 HCV genom
24	236	100.0	9707	21	AEG24771	Aeg24771 HCV genom
25	236	100.0	11036	18	AEC08849	Aec08849 Vector rF
26	236	100.0	11036	18	AEC08848	Aec08848 Vector rF
27	236	100.0	11102	21	AEG24773	Aeg24773 HCV chime
28	236	100.0	11111	18	AEC08838	Aec08838 Replicon
29	236	100.0	11111	18	AEC08839	Aec08839 Mutant re
30	236	100.0	11876	18	AEC08851	Aec08851 Vector rF
31	236	100.0	11876	18	AEC08850	Aec08850 Vector rF
32	236	100.0	11969	18	AEC08847	Aec08847 Vector rF
33	236	100.0	11969	18	AEC08846	Aec08846 Vector rF
34	236	100.0	12369	29	AQY14566	Aqy14566 Hepatitis
35	236	100.0	12376	29	AQY14581	Aqy14581 Hepatitis
36	236	100.0	13407	29	AQY14572	Aqy14572 Hepatitis
37	236	100.0	13612	29	AQY14573	Aqy14573 Hepatitis

38	236	100.0	13612	29	AQY14574	Aqy14574	Hepatitis
39	236	100.0	13623	29	AQY14571	Aqy14571	Hepatitis
40	236	100.0	13630	29	AQY14575	Aqy14575	Hepatitis
41	236	100.0	14671	29	AQY14568	Aqy14568	Hepatitis
42	236	100.0	14671	29	AQY14569	Aqy14569	Hepatitis
43	236	100.0	14683	29	AQY14567	Aqy14567	Hepatitis
44	236	100.0	14689	29	AQY14570	Aqy14570	Hepatitis
45	232.8	98.6	8024	18	ADV04736	Adv04736	Replicon

## ALIGNMENTS

## RESULT 1

ADV04745

ID ADV04745 standard; RNA; 236 BP.

XX

AC ADV04745;

XX

DT 24-FEB-2005 (first entry)

XX

DE Synthetic RNA #3.

XX

KW Replicon; virucide; hepatitis C virus infection; ss.

XX

OS Synthetic.

XX

PN WO2004104198-A1.

XX

PD 02-DEC-2004.

XX

PF 25-NOV-2003; 2003WO-JP015038.

XX

PR 26-MAY-2003; 2003JP-00148242.

XX

PR 19-SEP-2003; 2003JP-00329115.

XX

PA (TORA ) TORAY IND INC.

PA (TOKM-) TOKYO METROPOLITAN ORG MEDICAL RES.

XX

PA (UYMA-) UNIV MAINZ GUTENBERG JOHANNES.

XX

PI Wakita T, Kato T, Date T;

XX

DR WPI; 2005-013292/01.

XX

PT Novel replicon RNA, having sequence of 5' and 3' untranslated region and base sequence encoding NS3, NS4A, NS4B, NS5A and NS5B proteins on genomic

PT RNA of hepatitis C virus of genotype 2a, useful for treating hepatitis C

XX

PS Claim 3; SEQ ID NO 11; 197pp; Japanese.

XX

CC The invention relates to replicon RNA from genotype 2a of hepatitis C virus comprising a 5' untranslated region, a base sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and a 3' untranslated region. The invention also relates to a cell capable of reproducing the replicon involving transducing the replicon RNA to a cell, a method of producing a hepatitis C virus protein, a method of screening a substance that promotes or suppresses the reproduction of hepatitis C virus, involving culturing the replicon reproducing cell in the presence of a test substance, and detecting the reproduction of replicon RNA in the culture. Virucide. The replicon RNA is useful for

CC producing a replicon reproduction cell and for increasing the  
 CC reproduction efficiency of replicon RNA of hepatitis C virus of genotype  
 CC 2a. The cell and the replicon RNA are useful for producing a therapeutic  
 CC agent or a diagnostic agent for hepatitis C virus infection, for  
 CC producing a vaccine against hepatitis C virus infection and for screening  
 CC a substance that promotes or suppresses the reproduction of hepatitis C  
 CC virus. This sequence represents synthetic RNA used in the scope of the  
 CC invention.

XX

SQ Sequence 236 BP; 33 A; 55 C; 36 G; 0 T; 112 U; 0 Other;

Query Match 100.0%; Score 236; DB 18; Length 236;  
 Best Local Similarity 100.0%; Pred. No. 1.2e-25;  
 Matches 236; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCGGCACACUAGGUACACUCCAUAGCUAACUGUCCUUUUUUUUUUUUUUUUUUUU 60  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Db 1 AGCGGCACACUAGGUACACUCCAUAGCUAACUGUCCUUUUUUUUUUUUUUUUUUUU 60  
 Qy 61 UUU 120  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Db 61 UUU 120  
 Qy 121 UAUUCUACUU 180  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Db 121 UAUUCUACUU 180  
 Qy 181 UCCGUGAGCCGCAUGACUGCAGAGAGUGCCGUAACUGGUCUCUCUGCAGAUCAUGU 236  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Db 181 UCCGUGAGCCGCAUGACUGCAGAGAGUGCCGUAACUGGUCUCUCUGCAGAUCAUGU 236

## RESULT 2

AEC08836

ID AEC08836 standard; RNA; 239 BP.

XX

AC AEC08836;

XX

DT 03-NOV-2005 (first entry)

XX

DE HCV 3' UTR RNA.

XX

KW Virucide; Vaccine; Gene therapy; replicon; HCV infection; infection; ss.

XX

OS Hepatitis C virus.

XX

PN W02005080575-A1.

XX

PD 01-SEP-2005.

XX

PF 21-FEB-2005; 2005WO-JP003232.

XX

PR 20-FEB-2004; 2004JP-00045489.

XX

PA (TOKM-) TOKYO METROPOLITAN ORG MEDICAL RES.

PA

(TORA ) TORAY IND INC.

XX

PI Wakita T, Kato T, Date T, Miyamoto M, Tanabe J, Sone S;

XX

DR WPI; 2005-630375/64.

XX





DT 24-FEB-2005 (first entry)  
 XX  
 DE Replicon RNA #4.  
 XX  
 KW Replicon; virucide; hepatitis C virus infection; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO2004104198-A1.  
 XX  
 PD 02-DEC-2004.  
 XX  
 PF 25-NOV-2003; 2003WO-JP015038.  
 XX  
 PR 26-MAY-2003; 2003JP-00148242.  
 PR 19-SEP-2003; 2003JP-00329115.  
 XX  
 PA (TORA) TORAY IND INC.  
 PA (TOKM-) TOKYO METROPOLITAN ORG MEDICAL RES.  
 PA (UYMA-) UNIV MAINZ GUTENBERG JOHANNES.  
 XX  
 PI Wakita T, Kato T, Date T;  
 XX  
 DR WPI; 2005-013292/01.  
 XX  
 PT Novel replicon RNA, having sequence of 5' and 3' untranslated region and  
 PT base sequence encoding NS3, NS4A, NS4B, NS5A and NS5B proteins on genomic  
 PT RNA of hepatitis C virus of genotype 2a, useful for treating hepatitis C  
 PT virus infection.  
 XX  
 PS Example 1; SEQ ID NO 8; 197pp; Japanese.  
 XX  
 CC The invention relates to replicon RNA from genotype 2a of hepatitis C  
 CC virus comprising a 5' untranslated region, a base sequence encoding NS3  
 CC protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and a  
 CC 3' untranslated region. The invention also relates to a cell capable of  
 CC reproducing the replicon involving transducing the replicon RNA to a  
 CC cell, a method of producing a hepatitis C virus protein, a method of  
 CC screening a substance that promotes or suppresses the reproduction of  
 CC hepatitis C virus, involving culturing the replicon reproducing cell in  
 CC the presence of a test substance, and detecting the reproduction of  
 CC replicon RNA in the culture. Virucide. The replicon RNA is useful for  
 CC producing a replicon reproduction cell and for increasing the  
 CC reproduction efficiency of replicon RNA of hepatitis C virus of genotype  
 CC 2a. The cell and the replicon RNA are useful for producing a therapeutic  
 CC agent or a diagnostic agent for hepatitis C virus infection, for  
 CC producing a vaccine against hepatitis C virus infection and for screening  
 CC a substance that promotes or suppresses the reproduction of hepatitis C  
 CC virus. This sequence represents replicon RNA used in the scope of the  
 CC invention.  
 XX  
 SQ Sequence 7994 BP; 1668 A; 2383 C; 2231 G; 0 T; 1712 U; 0 Other;

Query Match 100.0%; Score 236; DB 18; Length 7994;  
 Best Local Similarity 100.0%; Pred. No. 7e-26;  
 Matches 236; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCGGCACACACUAGGUACACUCCAUAGCUAACUGUUCUUUUUUUUUUUUUUUUUUUUUU 60  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Db 7759 AGCGGCACACACUAGGUACACUCCAUAGCUAACUGUUCUUUUUUUUUUUUUUUUUUUUUU 7818

## ADV04741

<http://es.ScoreAccessWeb/GetItem.action?AppId=10558155&seqId=09323b67809b4052...> 12/1/2008

CC producing a replicon reproduction cell and for increasing the  
 CC reproduction efficiency of replicon RNA of hepatitis C virus of genotype  
 CC 2a. The cell and the replicon RNA are useful for producing a therapeutic  
 CC agent or a diagnostic agent for hepatitis C virus infection, for  
 CC producing a vaccine against hepatitis C virus infection and for screening  
 CC a substance that promotes or suppresses the reproduction of hepatitis C  
 CC virus. This sequence represents replicon RNA used in the scope of the  
 CC invention.

XX

SQ Sequence 8024 BP; 1676 A; 2389 C; 2239 G; 0 T; 1720 U; 0 Other;

Query Match 100.0%; Score 236; DB 18; Length 8024;  
 Best Local Similarity 100.0%; Pred. No. 7e-26;  
 Matches 236; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy      1 AGCGGCACACUAGGUACACUCCAUAGCUAACUGUUCUUUUUUUUUUUUUUUUUUUU 60
Db      7789 AGCGGCACACUAGGUACACUCCAUAGCUAACUGUUCUUUUUUUUUUUUUUUUUUUU 7848
      |||
Qy      61 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 120
Db      7849 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 7908
      |||
Qy      121 UAUUCUACUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 180
Db      7909 UAUUCUACUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 7968
      |||
Qy      181 UCCGUGAGCCGCAUGACUGCAGAGAGUGCCGUAACUGGUCUCUCUGCAGAUCAUGU 236
Db      7969 UCCGUGAGCCGCAUGACUGCAGAGAGUGCCGUAACUGGUCUCUCUGCAGAUCAUGU 8024
      |||

```

## RESULT 6

ADV04735

ID ADV04735 standard; RNA; 8024 BP.

XX

AC ADV04735;

XX

DT 24-FEB-2005 (first entry)

XX

DE Replicon RNA #1.

XX

KW Replicon; virucide; hepatitis C virus infection; ss.

XX

OS Synthetic.

XX

PN WO2004104198-A1.

XX

PD 02-DEC-2004.

XX

PF 25-NOV-2003; 2003WO-JP015038.

XX

PR 26-MAY-2003; 2003JP-00148242.

XX

PR 19-SEP-2003; 2003JP-00329115.

XX

PA (TORA ) TORAY IND INC.

XX

PA (TOKM-) TOKYO METROPOLITAN ORG MEDICAL RES.

XX

PA (UYMA-) UNIV MAINZ GUTENBERG JOHANNES.

XX

PI Wakita T, Kato T, Date T;

XX

DR WPI; 2005-013292/01.  
 XX  
 PT Novel replicon RNA, having sequence of 5' and 3' untranslated region and  
 PT base sequence encoding NS3, NS4A, NS4B, NS5A and NS5B proteins on genomic  
 PT RNA of hepatitis C virus of genotype 2a, useful for treating hepatitis C  
 PT virus infection.  
 XX  
 PS Claim 5; SEQ ID NO 1; 197pp; Japanese.  
 XX  
 CC The invention relates to replicon RNA from genotype 2a of hepatitis C  
 CC virus comprising a 5' untranslated region, a base sequence encoding NS3  
 CC protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and a  
 CC 3' untranslated region. The invention also relates to a cell capable of  
 CC reproducing the replicon involving transducing the replicon RNA to a  
 CC cell, a method of producing a hepatitis C virus protein, a method of  
 CC screening a substance that promotes or suppresses the reproduction of  
 CC hepatitis C virus, involving culturing the replicon reproducing cell in  
 CC the presence of a test substance, and detecting the reproduction of  
 CC replicon RNA in the culture. Virucide. The replicon RNA is useful for  
 CC producing a replicon reproduction cell and for increasing the  
 CC reproduction efficiency of replicon RNA of hepatitis C virus of genotype  
 CC 2a. The cell and the replicon RNA are useful for producing a therapeutic  
 CC agent or a diagnostic agent for hepatitis C virus infection, for  
 CC producing a vaccine against hepatitis C virus infection and for screening  
 CC a substance that promotes or suppresses the reproduction of hepatitis C  
 CC virus. This sequence represents replicon RNA used in the scope of the  
 CC invention.  
 XX  
 SQ Sequence 8024 BP; 1674 A; 2389 C; 2241 G; 0 T; 1720 U; 0 Other;

Query Match 100.0%; Score 236; DB 18; Length 8024;  
 Best Local Similarity 100.0%; Pred. No. 7e-26;  
 Matches 236; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      1 AGCGGCACACACUAGGUACACUCCAUAGCUAACUGUUCUUUUUUUUUUUUUUUUUUUU 60
      |||
Db      7789 AGCGGCACACACUAGGUACACUCCAUAGCUAACUGUUCUUUUUUUUUUUUUUUUUUUU 7848

QY      61 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 120
      |||
Db      7849 UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 7908

QY      121 UAUUCUACUUUCUUUCUUGGUGGCUCCAUUCUAGCCUAGUCACGGCUAGCUGUGAAAGG 180
      |||
Db      7909 UAUUCUACUUUCUUUCUUGGUGGCUCCAUUCUAGCCUAGUCACGGCUAGCUGUGAAAGG 7968

QY      181 UCCGUGAGCCGCAUGACUGCAGAGAGUGCCGUAACUGGUCUCUCUGCAGAUCAUGU 236
      |||
Db      7969 UCCGUGAGCCGCAUGACUGCAGAGAGUGCCGUAACUGGUCUCUCUGCAGAUCAUGU 8024

```

RESULT 7  
 AED43513  
 ID AED43513 standard; DNA; 8024 BP.  
 XX  
 AC AED43513;  
 XX  
 DT 15-DEC-2005 (first entry)  
 XX  
 DE Hepatitis C virus replicon, DNA template SEQ ID NO:2.  
 XX

KW RNA detection; RNA interference; hepatitis C virus infection;  
 KW antiinflammatory; hepatotropic; rna virus infection; virucide;  
 KW gastrointestinal disease; ds.  
 XX  
 OS Hepatitis C virus.  
 XX  
 PN WO2005095655-A1.  
 XX  
 PD 13-OCT-2005.  
 XX  
 PF 23-MAR-2005; 2005WO-US009959.  
 XX  
 PR 24-MAR-2004; 2004US-0555765P.  
 XX  
 PA (ACHI-) ACHILLION PHARM INC.  
 PA (SUNY/) SUN Y.  
 PA (YANG/) YANG W.  
 XX  
 PI Huang M;  
 XX  
 DR WPI; 2005-734191/75.  
 XX  
 PT Determining RNA synthesis inhibitors for a positive strand RNA virus,  
 PT comprises contacting a replicase complex, viral replicon template RNA,  
 PT labeled nucleotide analog, and test compound.  
 XX  
 PS Claim 21; SEQ ID NO 2; 70pp; English.  
 XX  
 CC The invention relates to a method of determining whether a compound  
 CC inhibits RNA synthesis of a positive strand RNA virus. The method  
 CC comprises: contacting an isolated replicase complex for the positive  
 CC strand RNA virus, an isolated viral replicon template RNA for the  
 CC positive strand RNA virus, a labeled nucleotide analog, and the test  
 CC compound, under conditions for in vitro RNA synthesis, to form a newly  
 CC synthesized RNA population comprising the labeled nucleotide analog;  
 CC detecting the newly synthesized RNA population comprising the labeled  
 CC nucleotide analog; quantitating the newly synthesized RNA population  
 CC comprising the labeled nucleotide analog to provide a test RNA amount;  
 CC and comparing the test RNA amount with a control RNA amount of a control  
 CC newly synthesized RNA population comprising the labeled nucleotide analog  
 CC produced in the absence of the test compound, where a decrease in the  
 CC test RNA amount compared to the control RNA amount indicates that the  
 CC test compound inhibits RNA synthesis of the positive strand RNA virus.  
 CC Contacting further comprises contacting with 2'-O-methyl-5-methyluridine-  
 CC 5'-triphosphate. The method further comprises providing the isolated  
 CC replicase complex and the isolated viral replicon template RNA by  
 CC transfecting a cell line with a viral replicon RNA or a DNA template for  
 CC a viral replicon to provide a transfected cell line, incubating the  
 CC transfected cell line under conditions for production of viral replicase  
 CC complexes, and isolating the replicase complexes and the viral replicon  
 CC template RNA from the cell membrane fraction of the transfected cells,  
 CC where the positive strand RNA virus is Hepatitis C Virus and the DNA  
 CC template for a viral replicon comprises a sequence of AED43512 to  
 CC AED43516 (SEQ ID NOS: 1-5). Also included are: a method for quantitating  
 CC newly initiated RNA of a positive strand RNA virus; and a kit, for  
 CC screening a test compound for inhibition of RNA synthesis of a positive  
 CC strand RNA virus, comprising an isolated replicase complex for the  
 CC positive strand RNA virus, an isolated viral replicon template RNA for  
 CC the positive strand RNA virus, instructions for use, and a buffer and  
 CC nucleoside triphosphates for production of newly synthesized viral  
 CC replicon RNA. The methods and kits are useful for determining whether a

CC test compound inhibits RNA synthesis of a positive strand RNA virus. The  
 CC present sequence represents Hepatitis C virus replicon, DNA template SEQ  
 CC ID NO:2.

XX

SQL Sequence 8024 BP; 1675 A; 2390 C; 2238 G; 1721 T; 0 U; 0 Other;

Query Match 100.0%; Score 236; DB 19; Length 8024;  
 Best Local Similarity 52.5%; Pred. No. 7e-26;  
 Matches 124; Conservative 112; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCGGCACACACUAGGUACACUCCAUAGCUAACUGUCCUUUUUUUUUUUUUUUUUUUU 60  
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
 Db 7789 AGCGGCACACACTAGGTACTCCATAGCTAACTGTTCTCTTTTTTTTTTTTTTTTTTTT 7848

Qy 61 UUU 120  
 :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
 Db 7849 TTTTTTTTTTTTTTTTTTTTTTTCTTTTTTTTTTTTTTTCCCTCTTCTCTCCCTCTCATCT 7908

Qy 121 UAUUCUACUU 180  
 :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
 Db 7909 TATTCTACTTTCTTTCTTGGTGGCTCCATCTTAGCCCTAGTCACGGCTAGCTGTGAAAGG 7968

Qy 181 UCCGUGAGCCGCAUGACUGCAGAGAGUGCCGUAACUGGUCUCUGCAGAUCAUGU 236  
 :|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:  
 Db 7969 TCCGTGAGCCGATGACTGCAGAGAGTGCCGTAACCTGGTCTCTCTGAGATCATGT 8024

# RESULT 8

AEL39639

ID AEL39639 standard; DNA; 8024 BP.

XX

AC AEL39639;

XX

DT 11-JUN-2007 (revised)

DT 28-DEC-2006 (first entry)

XX

DE HCV replicon DNA SEQ ID NO:15.

XX

KW Viral replication; NS3; replicon; ds.

XX

OS Hepatitis C virus.

XX

PN WO2006110762-A2.

XX

PD 19-OCT-2006.

XX

PF 11-APR-2006; 2006WO-US013503.

XX

PR 11-APR-2005; 2005US-0669872P.

XX

PA (ACHI-) ACHILLION.

XX

PI Huang M;

XX

DR WPI; 2006-814697/82.

DR

PC:NCBI; gi40714444.

XX

PT Identifying a mutant that is resistant to replicase complex defect  
 PT inducer comprises growing Hepatitis C Virus and identifying mutant that  
 PT is resistant to test compound and sensitive to nonstructural protein 5B  
 PT polymerase inhibitor.



XX  
 AC AER48939;  
 XX  
 DT 03-MAY-2007 (first entry)  
 XX  
 DE Hepatitis C virion-associated DNA from Fig 6A.  
 XX  
 KW ds; hepatitis C virus infection; hepatitis virus infection;  
 KW antiinflammatory; hepatotropic; virucide; gastrointestinal disease;  
 KW infection.  
 XX  
 OS Unidentified.  
 XX  
 PN WO2007013882-A2.  
 XX  
 PD 01-FEB-2007.  
 XX  
 PF 30-SEP-2005; 2005WO-US035487.  
 XX  
 PR 30-SEP-2004; 2004US-0615301P.  
 PR 06-JAN-2005; 2005US-0642210P.  
 PR 26-SEP-2005; 50US-00887766.  
 XX  
 PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.  
 XX  
 PI Liang TJ, Heller T, Saito S;  
 XX  
 DR WPI; 2007-292066/28.  
 XX  
 PT Front page title and author's abstract inconsistent, abstract based on  
 PT main claim. Patent office notified - deployable monitoring device for  
 PT close-up visual monitoring of scene, has self-righting mechanism  
 PT supported by base.  
 XX  
 PS Disclosure; Fig 17A; 61pp; English.  
 XX  
 CC This invention describes a novel self-righting housing which has a base  
 CC and an opposed end along an axis and can be used for close-up visual  
 CC monitoring of a scene. The housing has center of gravity about the base  
 CC so as to be self-righting along the axis. The housing is supported by the  
 CC base when self-righting. The video imaging device is engaged with the  
 CC housing to obtain the video image of a scene external to the housing. A  
 CC stabilizer extends outward of the base, to stop rotation of the housing  
 CC about the axis before the housing is righted and following deployment of  
 CC the housing to allow self-righting. A power source is connected to the  
 CC video imaging device. The housing is partially translucent to allow the  
 CC lens of video capture module to receive the video data of the scene over  
 CC 360deg field of view of the housing. The video imaging device is  
 CC responsive to visible light and infrared light. A light source within the  
 CC housing illuminates the scene. The video imaging device is configured to  
 CC be manually focused and responsive to a focus command from the remotely  
 CC located station via a transceiver module. A chemical sensor connected  
 CC with the transceiver module, acquires the chemical composition data from  
 CC the scene. A gimbal mechanism engaged between the video imaging device  
 CC and the housing is configured to pan, tilt and rotate the video imaging  
 CC device, to 30deg below the horizontal plane and 90deg above the  
 CC horizontal plane, in response to the motion of the scene detected by a  
 CC motion sensor. A spatial orientation device comprising a global  
 CC positioning system (GPS) device and a compass device, spatially orient  
 CC the scene with respect to the video imaging device. The invention can be  
 CC used for close-up visual monitoring of a scene such as industrial or



PT New isolated nucleic acid comprises a chimeric Hepatitis C Virus (HCV)  
 PT genome, useful for identifying anti-HCV therapeutic useful in vaccines  
 PT and diagnostics, and sequences of HCV associated with HCV pathogenesis.

XX  
 PS Claim 5; SEQ ID NO 3; 65pp; English.

XX  
 CC The invention relates to an isolated nucleic acid comprising a chimeric  
 CC Hepatitis C Virus (HCV) genome, where the chimeric HCV genome comprises  
 CC the structural core, E1 and E2 genes and nonstructural p7 and NS2 genes  
 CC from a first HCV strain, and a 5' non-coding region (NCR), non-structural  
 CC NS3, NS4A, NS4B, NS5A, NS5B genes, and a 3' non-coding region (NCR) from  
 CC a second HCV strain. The nucleic acid of the invention comprises a  
 CC sequence sharing 90% identity with any of fully defined sequences given  
 CC as SEQ ID NO. 1-5 in the specification. Also described are: (1) an  
 CC animal, viral particle, or vector comprising the isolated nucleic acid of  
 CC the invention; (2) a cell comprising the vector; (3) a method of  
 CC producing infectious HCV; (4) a method of screening for anti-HCV  
 CC therapeutics; and (5) a method of identifying HCV variants with improved  
 CC growth in cell culture. The nucleic acids of the invention are useful for  
 CC identifying anti-HCV therapeutics useful in vaccines and diagnostics, and  
 CC sequences of HCV associated with HCV pathogenesis. This sequence  
 CC represents a nucleic acid of the invention.

XX  
 SQ Sequence 9666 BP; 1925 A; 2909 C; 2736 G; 2096 T; 0 U; 0 Other;

Query Match 100.0%; Score 236; DB 21; Length 9666;  
 Best Local Similarity 52.5%; Pred. No. 6.8e-26;  
 Matches 124; Conservative 112; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCGGCACACACUAGGUACACUCCUAGCUAACUGUUCUUUUUUUUUUUUUUUUUUUU 60  
 Db 9431 AGCGGCACACACTAGGTACACTCCATAGCTAACTGTTTCCTTTTTCCTTTTTCCTTTT 9490  
 Qy 61 UUU 120  
 Db 9491 TTTTTCCTTTTTCCTTTTTCCTTTTTCCTTTTTCCTTTTTCCTTTTTCCTTTTTCCTTTT 9550  
 Qy 121 UAUUCUACUUCUUCUUGGUGGCUCAUCUAGCCUAGUCACGGCUAGCUGUGAAAGG 180  
 Db 9551 TATTCTACTTTCTTTCTGGTGGCTCCATCTTAGCCCTAGTACGGCTAGCTGTGAAGG 9610  
 Qy 181 UCCGUGAGCCGCAUGACUGCAGAGAGUGCCGUAACUGGUCUCUCUGCAGAUCAUGU 236  
 Db 9611 TCCGTGAGCCGATGACTGCAGAGAGTCCGTAACCTGGTCTCTCTGAGATCATGT 9666

# RESULT 11

AEK39272

ID AEK39272 standard; DNA; 9666 BP.

XX

AC AEK39272;

XX

DT 16-NOV-2006 (first entry)

XX

DE Hepatitis C Virus (HCV), DNA construct H77/JFH (I348S).

XX

KW genetic engineering; screening; therapeutic; diagnostic; vector; vaccine;

KW hepatitis C virus infection; gastrointestinal disease; infection;

KW antiinflammatory; hepatotropic; virucide; ds.

XX

OS Hepatitis C virus; (isolate H77).

<http://es/ScoreAccessWeb/GetItem.action?AppId=10558155&seqId=09323b67809b4052...>

## RESULT 12

AEK39273

ID AEK39273 standard; DNA; 9666 BP.

XX

AC AEK39273;

XX

DT 16-NOV-2006 (first entry)

XX

DE Hepatitis C Virus (HCV), DNA construct H77/JFH (S1107T).

XX

KW genetic engineering; screening; therapeutic; diagnostic; vector; vaccine;

KW hepatitis C virus infection; gastrointestinal disease; infection;

KW antiinflammatory; hepatotropic; virucide; ds.

XX

OS Hepatitis C virus; (isolate H77).

OS Hepatitis C virus; (isolate JFH-1).

OS Synthetic.

XX

PN WO2006096459-A2.

XX

PD 14-SEP-2006.

XX

PF 03-MAR-2006; 2006WO-US007454.

XX

PR 04-MAR-2005; 2005US-0658187P.

XX

PA (UYRQ ) UNIV ROCKEFELLER.

XX

PI Rice C, Lindenbach BD, Evans MJ, Jones C;

XX

DR WPI; 2006-627403/65.

XX

PT New isolated nucleic acid comprises a chimeric Hepatitis C Virus (HCV)  
 PT genome, useful for identifying anti-HCV therapeutic useful in vaccines  
 PT and diagnostics, and sequences of HCV associated with HCV pathogenesis.

XX

PS Claim 5; SEQ ID NO 5; 65pp; English.

XX

CC The invention relates to an isolated nucleic acid comprising a chimeric  
 CC Hepatitis C Virus (HCV) genome, where the chimeric HCV genome comprises  
 CC the structural core, E1 and E2 genes and nonstructural p7 and NS2 genes  
 CC from a first HCV strain, and a 5' non-coding region (NCR), non-structural  
 CC NS3, NS4A, NS4B, NS5A, NS5B genes, and a 3' non-coding region (NCR) from  
 CC a second HCV strain. The nucleic acid of the invention comprises a  
 CC sequence sharing 90% identity with any of fully defined sequences given  
 CC as SEQ ID NO. 1-5 in the specification. Also described are: (1) an  
 CC animal, viral particle, or vector comprising the isolated nucleic acid of  
 CC the invention; (2) a cell comprising the vector; (3) a method of  
 CC producing infectious HCV; (4) a method of screening for anti-HCV  
 CC therapeutics; and (5) a method of identifying HCV variants with improved  
 CC growth in cell culture. The nucleic acids of the invention are useful for  
 CC identifying anti-HCV therapeutics useful in vaccines and diagnostics, and  
 CC sequences of HCV associated with HCV pathogenesis. This sequence  
 CC represents a nucleic acid of the invention.

XX

SQ Sequence 9666 BP; 1926 A; 2911 C; 2734 G; 2095 T; 0 U; 0 Other;

Query Match 100.0%; Score 236; DB 21; Length 9666;  
 Best Local Similarity 52.5%; Pred. No. 6.8e-26;



CC noncoding region and a structural protein such as core protein, E1  
CC protein, E2 protein, p7 protein and NS2 protein, preferably core protein,  
CC E1 protein, E2 protein, and p7 protein of HCV and an arbitrary  
CC nonstructural protein and the DNA sequence encoding non structural  
CC protein such as NS2, NS3, NS4A, NS4B, NS5A and NS5B, preferably NS3,  
CC NS4A, NS4B, NS5A and NS5B and 3' noncoding region derived from HCV JFH1  
CC strain downstream of RNA polymerase promoter and further containing a DNA  
CC including RNA polymerase I terminator downstream into a cell, that allows  
CC HCV proliferation. The method is useful for producing an infectious HCV  
CC particle. The method enables high production (60 times) of infectious HCV  
CC particle. This sequence represents an DNA associated with the method of  
CC producing an infectious HCV particle.

SO Sequence 9666 BP; 1923 A; 2904 C; 2743 G; 2096 T; 0 U; 0 Other;

Query Match 100.0%; Score 236; DB 25; Length 9666;  
Best Local Similarity 52.5%; Pred. No. 6.8e-26;  
Matches 124; Conservative 112; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGCGGCACACACUAGGUACACUCCAUGUACUACUGUUCUUUUUUUUUUUUUUUUUUUU	60
Db	9431	AGCGGCACACACTAGTACACTCCATAGCTAACTGTTCTCTTTTTTTTTTTTTTTTTTT	9490
Qy	61	UU	120
Db	9491	TTTTTTTTTTTTTTTTTTTTTTCTTTTTTTTTTTTTTCCCTCTTCTCCTCTCATCT	9550
Qy	121	UAUUCUACUUUUUUUUUUUGUGGUCUCCAUCUUAAGCCUAGUACGCGUAGCUGUGAAAGG	180
Db	9551	TATTCTACTTTCTTTCTTGGTGGCTCCACTTTAGCCCTAGTCACGGCTAGCTGTGAAAGG	9610
Qy	181	UCCGUGAGCCGAUGACUGCAGAGAGUGCCGUAACUGGUGUCUCUGCAGAUAUGU	236
Db	9611	TCCGTGAGCCGCATGACTCGACGAGAGTGCCTGAACTGGTCTCTCGACGATCATGT	9666

RESULT 14

AFR08183

ID AFR08183 standard: DNA: 9666 BP.

XX

AC AFR08183;

XX

DT 31-MAY-2007 (first entry)

XX

DE Infectious HCV particle associated DNA SEQ ID NO 31.

XX

KW virus-like particle; virus production; hepatitis C virus infection;

KW virucide; ds.

XX

OS Synthetic.

XX

PN WO2007037428-A1.

XX

PD 05-APR-2007.

XX

PF 29-SEP-2006: 2006WO-JP319572

XX

PR 30-SEP-2005: 2005JP-00287646.

XX

PA (NINA-) JAPAN NAT INST INFECTIOUS DISEASES

PA (TOKM-) TOKYO METROPOLITAN ORG MEDICAL RES.

Query Match 100.0%; Score 236; DB 25; Length 9666;  
Best Local Similarity 52.5%; Pred. No. 6.8e-26;  
Matches 124; Conservative 112; Mismatches 0; Indels 0; Gaps 0;

```

RESULT 15
AFR08184
ID AFR08184 standard; DNA; 9666 BP.
XX
AC AFR08184;
XX
DT 31-MAY-2007 (first entry)
XX

```

Query Match 100.0%; Score 236; DB 25; Length 9666;  
Best Local Similarity 52.5%; Pred. No. 6.8e-26;  
Matches 124; Conservative 112; Mismatches 0; Indels 0; Gaps 0

[illegible]

Search completed: November 14, 2008, 10:58:17  
Job time : 25.4143 secs

12/1/2008